North America still dominates the chemotherapy market, with over 45% share. The US spends more on cancer drugs than any other country — for better and worse. But Asia‑Pacific is the fastest‑growing region, driven by rising cancer rates in China and India and expanding healthcare access. The chemotherapy market forecast predicts that Asia‑Pacific will grow at over 9% CAGR, catching up to Western markets.

What's different? In Asia, generic chemotherapy is more common, and costs are lower. Many patients pay out‑of‑pocket, so price sensitivity is high. The chemotherapy market analysis notes that oral chemo is especially popular in Asia, because it reduces hospital visits and fits busy urban lifestyles.

But challenges remain: counterfeit drugs, lack of access in rural areas, and cultural stigma around cancer. Governments are trying to fix this with national insurance schemes and public awareness campaigns.

The takeaway: chemotherapy is a global market, but access is uneven. If you live in a low‑resource setting, advocate for generic drugs and supportive care. No one should suffer from treatable cancer because of geography.